Daniel Soland just Acquired 10,000 shares of ACADIA Pharmaceuticals Inc. (ACAD), be careful if you are short!; KINAXIS ORDINARY SHARES CANADA (KXSCF) SI Decreased By 1.21%

Daniel Soland, the shareholder of Acadia Pharmaceuticals Inc, purchased 10,000 shares of the company, worth roughly $234,910 US Dollars, which is calculated based on a stock price of $23.5 per share. Now, Daniel Soland owns 10,000 shares which are about 0.01% of Acadia Pharmaceuticals Inc’s market cap (total dollar market value of all company’s outstanding shares).

KINAXIS INC ORDINARY SHARES CANADA (OTCMKTS:KXSCF) had a decrease of 1.21% in short interest. KXSCF’s SI was 423,100 shares in March as released by FINRA. Its down 1.21% from 428,300 shares previously. With 1,100 avg volume, 385 days are for KINAXIS INC ORDINARY SHARES CANADA (OTCMKTS:KXSCF)’s short sellers to cover KXSCF’s short positions. The SI to KINAXIS INC ORDINARY SHARES CANADA’s float is 1.72%. It closed at $67.67 lastly. It is down 0.00% since March 3, 2017 and is . It has underperformed by 16.70% the S&P500.

Kinaxis Inc. provides cloud-based software for supply chain operations. The company has market cap of $1.81 billion. The firm offers RapidResponse, which provides supply chain planning and analytics capabilities for managing various supply chain management processes, including demand planning, supply planning, inventory management, order fulfillment, and capacity planning. It has a 108.97 P/E ratio. It also offers professional services, such as implementation, technical, and training services, as well as maintenance and support services to its software products.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company has market cap of $2.94 billion. The Company’s lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson??s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer??s disease psychosis. It currently has negative earnings. The firm has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain.

Since October 4, 2017, it had 0 insider buys, and 4 selling transactions for $5.71 million activity. $751,543 worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares were sold by Brege Laura. Another trade for 74,321 shares valued at $2.24 million was made by Baity Glenn on Tuesday, January 2.

Among 12 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. ACADIA Pharmaceuticals has $61.0 highest and $34 lowest target. $50.54’s average target is 113.43% above currents $23.68 stock price. ACADIA Pharmaceuticals had 33 analyst reports since August 7, 2015 according to SRatingsIntel. J.P. Morgan maintained it with “Buy” rating and $50.0 target in Thursday, October 5 report. The firm has “Neutral” rating given on Friday, August 7 by Piper Jaffray. The rating was maintained by Piper Jaffray on Thursday, October 5 with “Buy”. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Buy” rating given on Tuesday, November 8 by Bank of America. The rating was maintained by Cowen & Co with “Buy” on Monday, November 13. The rating was initiated by Goldman Sachs with “Neutral” on Friday, November 11. Needham maintained the stock with “Buy” rating in Friday, September 15 report. The rating was maintained by JP Morgan on Friday, September 4 with “Buy”. As per Sunday, August 9, the company rating was maintained by Cowen & Co. The stock has “Buy” rating by Cowen & Co on Wednesday, October 4.

The stock increased 3.05% or $0.7 during the last trading session, reaching $23.68. About 3.80 million shares traded or 97.61% up from the average. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 15.19% since March 3, 2017 and is downtrending. It has underperformed by 31.89% the S&P500.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: